If the FDA approves use of zuranolone, the first fast-acting oral medication for postpartum depression and major depressive disorder, the drug will become part of Cleveland Clinic’s s robust toolkit for caring for patients with those conditions.
Poorly controlled postoperative pain following cesarean delivery reduces likelihood of successful in-hospital breastfeeding, according to a recent study. In this article, anesthesiologist Alparslan Turan, MD, discusses his research and Ob/Gyn Jennifer Eaton, DO, discusses efforts to manage pain while reducing opioid use.
Screening NICU parents for depression only may mean that those with debilitating stress or anxiety may go undiagnosed, according to a recent study. Neonatologist Anirudha Das, MD, explains his research and efforts in place to support vulnerable parents.
This novel infusion therapy could be a breakthrough for postpartum depression, but its administration is complex and highly regulated. Three psychiatrists outline how we’ll introduce it in our health system.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Brexanolone injection, which recently received FDA approval as a treatment for postpartum depression, is promising though questions remain.
Counseling at-risk women can prevent pregnancy-related depression. Rebecca Starck, MD, explains the new recommendation from the US Preventive Task Force.